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Abstract 
Background: Primary cardiac angiosarcoma is extremely aggressive; however, it is often misdiagnosed because of its 
rarity. For locally advanced tumors, doxorubicin-based chemotherapy regimens are the standard of treatment, even if 
the gain in term of progression-free survival is limited and is no longer than 5 months.
Case presentation: We report the case of a Caucasian 23-year-old man with locally advanced cardiac angiosarcoma 
who underwent radical surgical resection after a prolonged response to weekly docetaxel and complementary 
radiotherapy.
Conclusion: Combined treatment with weekly docetaxel and radiotherapy may be a valid alternative for the treat-
ment of locally advanced cardiac angiosarcoma; the combination can lead to radical surgical resections, avoiding the 
cumulative cardiotoxicity of antracycline-based regimens.
Keywords: Angiosarcoma, Soft tissue sarcoma, Taxanes, Docetaxel, Cardiac tumors
© 2015 Minichillo et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Primary cardiac neoplasms are extremely rare, with an 
incidence of approximately 0.0001–0.030%. Although 
75% of these tumors are benign, the remaining 25% 
are malignant, and angiosarcoma is the most frequent 
histotype.
Males are affected more often than females in a ratio 
of 2–3:1, and these neoplasms occur more commonly 
in individuals younger than 65  years. The mean sur-
vival time is 4 months, and most patients die within few 
months of diagnosis.
From a clinical point of view, primary cardiac neo-
plasms frequently occur with non-specific symptoms, 
such as dyspnea, weight loss, fatigue, anemia, and chest 
pain. In most cases, an early diagnosis is difficult. In addi-
tion to physical examination, electrocardiogram (ECG), 
cardiac catheterization and imaging studies such as com-
puted tomography (CT), nuclear magnetic resonance 
(NMR) and echocardiography are the gold standard for 
diagnosis. Moreover, transthoracic echocardiography 
can evaluate the location, shape, size and mobility of the 
mass. Transesophageal echocardiography provides infor-
mation about the insertion point of the tumor. Cardiac 
NMR is a more specific and sensitive tool than CT scan 
for diagnosis. NMR evaluation can determine whether 
the angiosarcoma is hemorrhagic or necrotic. Endomyo-
cardial biopsies are usually negative, so a surgical explo-
ration and intraoperative frozen sections are strongly 
suggested.
Current management of cardiac angiosarcoma, 
although still controversial, uses a multimodality 
approach, combining surgery, chemotherapy and radio-
therapy. Radical resection followed by adjuvant radio-
therapy represents the standard treatment in cases of 
limited disease, although the majority of patients present 
with locally advanced or metastatic disease [1, 2]. In case 
of locally advanced disease, integrated treatment with 
chemotherapy and radiotherapy may lead to shrinkage of 
the mass, allowing for radical surgery. Doxorubicin-based 
regimens are the gold standard treatment for locally 
advanced and metastatic angiosarcoma; however, the 
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known cardiotoxicity of the anthracyclines can limit their 
use, especially in patients with intracardiac disease [3]. 
Taxanes alone or in combination with gemcitabine have 
shown high antitumor activity in angiosarcoma, although 
they generally have limited activity in soft tissue sarco-
mas. According to these data, taxanes are considered an 
alternative option for angiosarcoma. Until now, little evi-
dence has been accumulated about the activity of taxanes 
in metastatic or locally advanced angiosarcoma [4–7]. 
We report the case of a Caucasian 23-year-old man with 
locally advanced cardiac angiosarcoma who underwent 
radical surgical resection after a prolonged response to 
weekly docetaxel and complementary radiotherapy.
Case presentation
In April 2008, a healthy Caucasian 23-year-old man went 
to the emergency room for the sudden onset of dyspnea 
on exertion, fatigue, chest discomfort, fever, and night 
sweats. Upon physical examination, his vital signs were 
stable, with only mild tachycardia (heart rate 96/min). 
There were no palpable lymph nodes. Jugular venous 
pressure, carotid upstroke, and heart sounds were not 
clinically relevant. There were no appreciable murmurs. 
Respiratory and abdominal objective examinations were 
normal. A transthoracic echocardiogram revealed the 
presence of a profuse pericardial effusion; therefore an 
evacuative pericardiocentesis was performed, draining 
approximately 900 mL of serum blood material. A subse-
quent chest CT scan showed a solid and expansive mass, 
about 8.4  cm in diameter with a partial endocavitary 
development in the right atrium, associated with multiple 
mediastinal adenopathies and three noncalcified pulmo-
nary micronodules. An NMR scan confirmed the previ-
ous CT findings (Fig. 1), and a subsequent CT- Positron 
Emission Tomography (PET) scan showed high glucose 
uptake in the mass (max standardized uptake value—
SUV = 6.5). The histological examination performed by 
multiple biopsies of the lesion revealed a malignant mes-
enchymal neoplasm compatible with angiosarcoma.
Surgical treatment with radical intent was initially 
excluded, given the size of the mass, its location close to 
the coronary ostium and the suspicion of extracardiac 
involvement. Therefore, a combined radiochemothera-
peutic neoadjuvant treatment was planned. In order to 
preserve myocardial function as much as possible to 
allow for a subsequent surgical resection, doxorubicin 
was avoided, and first-line treatment with docetaxel was 
chosen. From June 2008 to September 2008, the patient 
was treated with four cycles of weekly docetaxel (35 mg/
mq) with excellent tolerance. The subsequent NMR 
revaluation showed the disappearance of pulmonary 
nodules and a reduction of the atrial mass by about 1 cm. 
Subsequently, percutaneous conformal radiotherapy at 
a total dose of 5,400 centigray (cGy), with a daily frac-
tionation of 180  cGy was performed, followed by 13 
additional infusions of weekly docetaxel at the previous 
dose. Although the radiological revaluation confirmed 
a further reduction in size of the cardiac mass and a 
reduction in size of mediastinic adenopathies, the sur-
gical resection was still excluded. Therefore the patient 
continued chemotherapy, receiving a total of 24 cycles of 
weekly docetaxel, until May 2009. Since a further reduc-
tion of 1.2  cm in size of the atrial mass was found by 
NMR (Fig.  2) and CT-PET scan, the surgical treatment 
was performed in July 2009. After surgery, the patient 
was treated again with weekly docetaxel for a total of 10 
cycles in the adjuvant setting with overall good tolerance. 
A follow-up radiological revaluation (NMR, PET) did not 
show any signs of recurrence. A close follow-up was set 
during which several evacuative thoracenteses were per-
formed because of a recurrent bilateral neoplastic pleural 
effusion until the patient died in April 2010 of respiratory 
failure about 2 years after diagnosis. The last radiological 
assessment showed progressive disease with pleural and 
liver metastasis.
Discussion
Doxorubicin-based chemotherapy represents the stand-
ard medical treatment of cardiac angiosarcoma, even 
Fig. 1 Nuclear magnetic resonance imaging before neoadjuvant 
therapy with docetaxel.
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if the long-term benefit of chemotherapy and/or radio-
therapy is still unsettled. However, given the high tumor 
aggressiveness, a multimodal approach seems to be 
favoured. Several studies reported survival times ranging 
from 12 to 30 months with the use of various combina-
tions of surgery, chemotherapy, radiation and/or trans-
plant in cases of locally advanced or metastatic disease 
[8]. In case of limited disease, after radical resection, a 
multidisciplinary approach with adjuvant chemotherapy 
and radiotherapy may improve overall survival [9, 10].
At present, chemotherapeutic regimens for cardiac 
angiosarcoma are the same as for all soft tissue sarco-
mas. Currently, the standard treatment for metastatic or 
locally advanced cardiac angiosarcoma is doxorubicin, 
even if the benefit in terms of survival is modest (pro-
gression-free survival of about 5 months).
The role of radiotherapy in combination with 
chemotherapy is still controversial in cases of locally 
advanced disease, given the high cumulative risk of 
cardiotoxicity due to the potential radiation-induced 
cardiotoxicity added to the known cardiotoxicity of 
anthracycline-based therapy. High doses of radiation 
to improve control of local tumor increase the risk of 
severe adverse events.
The most effective method to improve the outcome 
of cancer radiation therapy is to concentrate the dose of 
radiation only on the tumor. This improves local tumor 
control and also reduces adverse events [6].
Given the promising results showing high activity of 
taxanes in angiosarcoma, some evidence on the efficacy 
of taxanes in cardiac angiosarcoma has recently been 
accumulated. Taxanes can be used as radiosensitizer 
agents to decrease the adverse effects of high-dose stand-
ard fractionated radiotherapy [6]. In 2008, Nakamura 
et al. noted a durable response of 12 months using radia-
tion with concomitant and then maintenance docetaxel 
[7]. In a case report in 2011, Suderman et  al. observed 
a partial response with a progression-free survival of 
16 months [6]. A good response has also been obtained 
using concomitant radiochemotherapy with carboplatin 
and paclitaxel [5].
Similar to the above data, our case report supports the 
use of weekly docetaxel as first-line treatment for locally 
advanced primary cardiac angiosarcoma, suggesting 
its efficacy especially when the goal is radical surgical 
resection, which represents the most important factor 
affecting the prognosis of cardiac angiosarcoma, which 
otherwise is inevitably unfavourable.
Despite these data, the underlying mechanism of action 
of taxanes in angiosarcoma remains unclear. It is already 
known that the taxanes are also effective in patients with 
Kaposi’s sarcoma, another vascular-derived tumor. In 
vitro, microtubule-targeted drugs exhibit potent antian-
giogenic activity at a low concentration. Pasquier et  al. 
characterized two distinct effects of paclitaxel on human 
endothelial cells: cytostatic effects at low concentrations 
and cytotoxic effects at high concentrations. The cyto-
static effect is associated with increased mitochondrial 
membrane potential, p53 overexpression, and modifica-
tion of the Bax/Bcl-2 ratio, whereas the cytotoxic effect 
involves inhibition of endothelial cell proliferation with-
out inducing apoptosis and without any structural modi-
fication of the microtubule network [11]. Therefore, it 
can be assumed that taxanes may also act as antiangio-
genic agents in cardiac angiosarcoma.
Conclusion
The overall prognosis for patients with cardiac angiosar-
coma is generally poor due to its local aggressiveness and 
its early metastatic potential. Until now, surgical resec-
tion seems to provide the best chance for prolonging sur-
vival. Even if doxorubicin-based chemotherapy remains 
the treatment of choice in unresectable and metastatic 
soft tissue sarcoma or locally advanced cardiac angiosar-
coma, this regimen may be associated with a high risk of 
cumulative cardiotoxicity, resulting in less chance of radi-
cal surgery.
Our case report would suggest that combined treat-
ment with weekly docetaxel and radiotherapy may be a 
Fig. 2 Nuclear magnetic resonance imaging after neoadjuvant 
therapy with docetaxel (24 administrations).
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valid alternative for the treatment of locally advanced 
cardiac angiosarcoma. This combination can lead to radi-
cal surgical resection, avoiding the cumulative cardiotox-
icity of anthracycline-based regimens.
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